Table 6 Base case cost-effectiveness (95% CI) of ART compared with no-ART
From: Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia
Strategy | Life time Cost $ | Life time incremental cost$ | Life years gain | Incremental life years gain | Cost effectiveness ($) | Incremental Cost Effectiveness ratio (ICER $) | % change from base case ICER |
|---|---|---|---|---|---|---|---|
Undiscounted | |||||||
no-ART | 265(86–1148) | 2.3(1.95–2.73) | 114(38–504) | ||||
ART | 2479(1214–4828) | 2215(771–4635) | 9.4(8.67–10.05) | 7.1(6.24–7.83) | 265(130–513) | 314(111–654) | |
Discounted at 3% | |||||||
no-ART | 247(80–1008) | 2.2(1.83–2.56) | 114(37–471) | ||||
ART | 2028(1000–3868) | 1780(577–3710) | 7.7(7.15–8.18) | 5.5(4.85–6.13) | 265(131–508) | 325(106–680) | 3.5 |